News

InBio and Beckman Coulter Partner to Advance Food Allergy Diagnostics

InBio, a global leader in high-quality, purified allergen proteins, and Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, are collaborating to enhance the performance of basophil activation tests (BAT) for food allergy research. The collaboration integrates InBio’s Food Protein Standards and purified allergens with the Next-Generation Basophil Activation Test (BAT) platform from Beckman Coulter Life Sciences.

InBio’s Food Protein Standards and purified allergen components are potent, biologically active proteins derived from foods such as peanut, egg, milk, tree nuts, and shellfish. These reagents are a critical component for BAT tests, and are validated for immunological consistency, ensuring reproducibility in high-sensitivity assays.

The Next-Generation BAT* by Beckman Coulter Life Sciences is a research use only breakthrough in functional allergy testing that offers researchers a powerful tool to assess allergic sensitization and reactivity with greater precision. Leveraging advanced flow cytometry and automation to measure basophil activation in response to allergen exposure, the Next-Generation BAT is an in vitro alternative to oral food challenges. The integration of InBio’s food proteins ensures consistency in allergen stimulation, reducing variability and improving test interpretation.

The Next-Generation BAT powered by InBio allergens can test for multiple allergens at once through a blood draw — saving hours of food testing and exposure to potentially harmful reactions.

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation